SGX:O6Z - Lonza (SGD 79.97) 1 Followers LONZA GROUP LTD
Sector: Health Technology, Industry: Biotechnology

Add to WatchList

Lonza's core profits rose 9.5% to $720.6m in H1

25 Jul 2019 - Singapore Business Review
Its pharma biotech & nutrition segment recorded 10.8% sales growth. Swiss biotech and pharma company Lonza saw profits climb 9.5% YoY to $720.6m (CHF520m) in H1 2019 from $658.2m (CHF475m) in 2018, an SGX filing revealed. Its total sales went up 6.4% YoY to $4.12b (CHF2.98b) from $3.87b (CHF2.8b) in ...

Lonza: Reports A Strong Third Quarter & Capsugel Integration On Track.

26 Oct 2017 - ShareInvestor Express
Continued strong performance in Q3 2017 for Lonza standalone as expected. Both segments on track to deliver full-year targets with offerings along the healthcare continuum adding to the other growth drivers. Outlook 2017 for Lonza standalone, which was already upgraded in April 2017, is confirmed. Capsugel ...

Lonza: Acquires Micro-Macinazione To Create The Global Leader In Micronization Capacity And Capabilities.

4 Aug 2017 - ShareInvestor Express
Lonza has acquired Micro-Macinazione, one of Europe's leading contract manufacturers providing micronization of active ingredients for the pharmaceutical and fine chemical industries. Micro-Macinazione, which had sales of ~ CHF 20 million in 2016, has 120 employees and is based in Monteggio, Switzerland. ...

Lonza: Prices EUR700 Million & USD200 Million Multi Tranche "Schuldschein" Loan.

4 Aug 2017 - ShareInvestor Express
Lonza Group Ltd announced the pricing of its multi-tranche "Schuldschein" loan with a total size of EUR 700 million and USD 200 million at competitive market terms. The EUR tranches have maturities of 4 and 6 years respectively with fixed and variable coupons. The USD tranches have maturities of 5 (variable ...

Lonza: Completes Acquisition Of Capsugel To Create Leading Integrated Solutions Provider To The Global Pharma & Consumer Healthcare Industries.

6 Jul 2017 - ShareInvestor Express
Acquisition aligns closely with Lonza's strategy to accelerate Lonza's growth and ability to deliver value along the healthcare continuum. Transaction price of USD 5.5 billion, including refinancing of existing Capsugel debt of approximately USD 2 billion...

Lonza: Prices CHF235 Million Dual Tranche Straight Bonds.

15 Jun 2017 - ShareInvestor Express
Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel, announced the pricing of its dual tranche CHF 235 million straight bonds. The bonds have a maturity of 4 and 7 years respectively with coupons of 0.200% and 0.700%...

Lonza: Launches Rights Offering.

26 Apr 2017 - ShareInvestor Express
Lonza announced that the Board of Directors determined the final terms of the capital increase by way of a rights offering...

Lonza: Announces Results Of The 2017 Annual General Meeting, All Motions Proposed By Board Of Directors Accepted.

26 Apr 2017 - ShareInvestor Express
235 shareholders attended, representing 59.96% of the share capital. Shareholders re-elected all existing members of the Board of Directors except for Thomas Ebeling, who did not stand for re-election, and approved the new election of Albert M. Baehny. Rolf Soiron was re-elected as Board Chairperson ...

Lonza: Starts 2017 With Outstanding First Quarter.

25 Apr 2017 - ShareInvestor Express
Strong start in Q1 paves way for double-digit organic sales growth for first half year. CORE EBIT growth expected to be even stronger than sales growth for first half of 2017. Pharma&Biotech with strong performance in revenue and profitability. Specialty Ingredients with robust growth and profitability ...

Lonza: Successfully Places 5 Million New Shares, Raising Gross Proceeds Of CHF865 Million.

1 Feb 2017 - ShareInvestor Express
Lonza Group AG has successfully placed 5.0 million new shares by way of an accelerated bookbuilding procedure with selected investors in Switzerland and outside of Switzerland to institutional investors and qualified institutional buyers, in reliance on Regulation S and 144A of the U.S. Securities Act...
Price Simulation

What happens (e.g. Current Yield) if the price becomes X?

My Notes

You currently do not have notes about this stock.

Dividends Tax Rate
Tax Rate (%)

Min Commission (SGD)

Past Transactions Add Transactions

You do not have past transactions for this stock.

Shared Portfolios Stats
All Shared Portfolios
0% holds O6Z (0/210)
0% recent buy involves O6Z (0/180)
0% recent sell involves O6Z (0/98)

SGD NA is median buy price (0/210)
SGD NA is recent median buy price (0/180)
SGD NA is recent median sell price (0/98)

*recent means in the last 14 days.